REG - Scancell Hlds - Appointment of Dr Florian Reinaud to the Board

Scancell HoldingsAnnouncement

10/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240710:nRSJ7654Va&default-theme=true

RNS Number : 7654V  Scancell Holdings Plc  10 July 2024

10 July 2024

 

Scancell Holdings plc

("Scancell" or the "Company")

 

 

Appointment of Dr Florian Reinaud to the Board of Directors

 

Dr Reinaud brings over 20 years of executive, non-executive and financial
experience from the healthcare sector

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer, today announces that Dr Florian Reinaud, of Redmile
Group, LLC ("Redmile") has been appointed as a Non-Executive Director to
Scancell's Board of Directors (the "Board").

 

Florian is a highly accomplished life sciences professional who brings over 20
years of leadership and investment experience across established
pharmaceutical companies, start-ups and healthcare investment organisations.
He is currently on the investment team at Redmile, an investment firm that
focuses on the healthcare sector. Florian began his career as a medical doctor
in the NHS before moving to Schroders Salomon Smith Barney, Citigroup's
European investment banking arm, working as an equity analyst covering the
pan-European medtech and healthcare services. He then transitioned to the
healthcare team at Apax Partners in Paris, advising on and executing venture
and late-stage investments.

 

Following his time at Apax, Partners, Florian became the first CFO of
Paris-based DBV technologies, a biopharmaceutical specialising in allergy
diagnosis and treatment, and then went on to serve as Partner at CDC
Innovation Capital, a French venture capital firm focused on investments in
healthcare services, for six years. He later co-founded and served as CEO of
Concilio, a medical concierge service, for six years, before joining Redmile.

 

Florian holds a BA (hons) in Physiology from Oxford University, as well as a
medical degree from Imperial College London School of Medicine.

 

Dr Jean-Michel Cosséry, Non-Executive Chairman of Scancell said: "On behalf
of the Board, I am pleased to welcome Florian to Scancell, where he will
represent one of the Company's key investors. His broad biopharmaceutical
industry and financial experience, coupled with his strong relationships with
the investment community and first-hand experience in the medical field, will
be invaluable as we continue to advance our lead assets through later stage
clinical development, and I am confident he will add significant value to the
Company."

 

Additional Information

 

In accordance with the AIM Rules, the following information required to be
disclosed in relation to Florian Reinaud is set out below. Other than this
information, there is no further information required to be disclosed under
paragraph (g) of Schedule Two of the AIM Rules.

 

Full name and age: Florian Reinaud, aged 50

 

 Current Directorships  Previous Directorships (last 5 years)
 Sensome SAS            Concilio

 Sensorion SA

 Hansa Biopharma AB

 

Dr Florian Reinaud does not have an interest in any ordinary shares or share
options in Scancell.

 

 For further information, please contact:
 Scancell Holdings plc                                                    +44 (0) 20 3709 5700
 Professor Lindy Durrant, CEO

 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Panmure Liberum Limited (Nominated Advisor and Joint Broker)             +44 (0) 20 7886 2500
 Emma Earl, Freddy Crossley, Will Goode, Mark Rogers (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Broker)                                           +44 (0) 20 3705 9330
 David Wilson/Claes Spang/Satheesh Nadarajah/Erland Sternby

 ICR Consilium                                                            +44 (0) 20 3709 5700
 Mary-Jane Elliott/Angela Gray/Lindsey Neville                            scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer. The Company is building a pipeline of innovative products by utilising
its four technology platforms: Moditope® and ImmunoBody® for vaccines and
GlyMab® and AvidiMab® for antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope® and
ImmunoBody® ) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab® ) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab® ).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOARLMMTMTIMTFI